Recent findings published in the Annals of Internal Medicine reveal that retatrutide has the potential to outperform current treatments like Ozempic and Wegovy in promoting weight loss. In trials reviewed by researchers from McGill University, retatrutide demonstrated weight reductions of up to 22.1% of participants' starting weight within 48 weeks
Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V
For screened, appropriate candidates administered under medical oversight, IV therapy is generally well tolerated, with temporary effects like mild bruising at the site or a cool sensation during infusion
consistency of dosing matters more than form
Many packaging strategies today were built for a different type of consumer one who bought larger portions, relied on multi-serve formats, and valued volume as a form of convenience
Neuropathic symptoms improved significantly